MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3138/canlivj-2022-0040

Медицинская библиотека · Canadian liver journal · 2023

Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.

Snell Gaelen, Marshall Alison D, van Gennip Jennifer, Bonn Matthew, Butler-McPhee Janet, Cooper Curtis L, Kronfli Nadine, Williams Sarah, Bruneau Julie, Feld Jordan J, Janjua Naveed Z, Klein Marina, Cunningham Nance, Grebely Jason, Bartlett Sofia R

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Direct-acting antiviral (DAA) therapies have simplified HCV treatment, and publicly funded Canadian drug plans have eliminated disease-stage restrictions for reimbursement of DAA therapies. However other policies which complicate, delay, or prevent treatment initiation still persist. We aim to describe these plans' existing reimbursement criteria and appraise whether they hinder treatment access.

METHODS

We reviewed DAA reimbursement policies of 16 publicly funded drug plans published online and provided by contacts with in-depth knowledge of prescribing criteria. Data were collected from May to July 2022. Primary outcomes were: (1) if plans have arranged to accept point-of-care HCV RNA testing for diagnosis; testing requirements for (2) HCV genotype, (3) fibrosis stage, and (4) chronic infection; (5) time taken and method used to approve reimbursement requests; (6) providers eligible to prescribe DAAs; and (7) restrictions on re-treatment.

RESULTS

Fifteen (94%) plans have at least one policy in place which limits simplified HCV treatment. Many plans continue to require results of genotype or fibrosis staging, limit eligible prescribers, and take longer than 1 day to approve coverage requests. One plan discourages treatment for re-infection.

CONCLUSION

Reimbursement criteria set by publicly funded Canadian drug plans continue to limit timely, equitable access to HCV treatment. Eliminating clinically irrelevant pre-authorization testing, expanding eligible prescribers, expediting claims processing, and broadening coverage of treatment for reinfection will improve access to DAAs. The federal government could further enhance efforts by introducing a federal HCV elimination strategy or federal high-cost drug PharmaCare program.

Для цитирования: Snell Gaelen, Marshall Alison D, van Gennip Jennifer, Bonn Matthew, Butler-McPhee Janet, Cooper Curtis L, Kronfli Nadine, Williams Sarah, Bruneau Julie, Feld Jordan J, Janjua Naveed Z, Klein Marina, Cunningham Nance, Grebely Jason, Bartlett Sofia R. Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.. Canadian liver journal. 2023. DOI: 10.3138/canlivj-2022-0040.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.